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Background: Global challenges related to access and benefit sharing (ABS) of biological
resources have become a key concern in the area of research on herbal medicines,
ethnopharmacology, drug discovery, and the development of other high value products
for which Intellectual Property protection can be secured. While the Convention on
Biological Diversity (CBD, Rio 1992) has been recognized as a huge step forward, the
implementation of the Nagoya Protocol (NP) and of new forms of collaboration often
remain unresolved, especially in the context of “the fair and equitable sharing of benefits
arising from the utilization of genetic resources” (Convention on Biological Diversity, 2011).
The vision and the specific implementation of this international treaty vary from country to
country, which poses additional challenges.
Aims: Using a case study approach, in this analysis we aim at understanding the specific
opportunities and challenges for implementing international collaborations regarding ABS
in six Latin American countries—Chile, Colombia, Guatemala, México, Panama, and Peru.
Based on that analysis, we provide recommendations for the path ahead regarding
international collaborations under ABS agreements in ethnopharmacological research.
Results and Discussions: The implementation of the NP varies in the six countries; and
while they are all rich in biodiversity, access and benefit sharing mechanisms differ
considerably. There is a need to engage in a consultation process with stakeholders, but
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this has often come to a halt. Institutional infrastructures to implement national policies are
weak, and the level of knowledge about the NP and the CBDwithin countries remains limited.
Conclusions: Different policies in the six countries result in very diverse strategies and
opportunities relating to the equitable use of biodiversity. A long-term strategy is required
to facilitate a better understanding of the treaties and the resulting opportunities for a fairer
development and implementation of transparent national polices, which currently differ in
the six countries. So far, the benefits envisioned by the CBD and the NP remain unfulfilled
for all stakeholders involved including local communities.
Keywords: Nagoya Protocol, benefit sharing, traditional medicine, Access and Benefit Sharing (ABS), natural
products, biological resources
INTRODUCTION
Ethnopharmacology and, more broadly, natural product
research, relies on the access to resources, especially in
biodiversity rich regions. Research in this field spans the whole
range from, in essence, basic research to studies strictly targeting
the commercial development of new products (Heinrich, 2000).
It is now governed by a range of international treaties including
the Convention on Biological Diversity (CBD) and the Nagoya
Protocol (NP). The NP specifically calls for the promotion and
safeguarding of “the fair and equitable sharing of benefits arising
from the utilization of genetic resources” (Secretariat of the
Convention on Biological Diversity, 2011). Therefore, a core
focus is now on such benefits which can be commercial or non-
commercial. In the current debate, commercial applications are
defined widely to include those where there is a long-term
potential for a commercial use, but no intention from the
researchers to do so (including phytochemical-pharmacological
studies). With the nearly global recognition and implementation
of the CBD (Rio Convention of 1992, https://www.cbd.int/
convention/text/), relationships between nations and territories
with regard to the use of biodiversity and its sustainable
development have been set on a new base. Grassroot initiatives
played a key role in these developments, which aimed to overcome
centuries of exploitative relationships often driven by colonial
powers. Predating this international treaty are numerous
academic and Non-governmental organization (NGO) initiatives
including, most importantly, the Declaration of Belem of 1988
(http://www.ethnobiology.net/what-we-do/core-programs/
global-coalition-2/declaration-of-belem/, see also Posey and
Dutfield (1996) that called for a recognition of indigenous rights
and for increased support for research on conservation and
management programs. Similarly, Tobin (2008) and others
highlighted the importance of customary law in protecting
traditions. Subsequently, a series of international treaties and
protocols [especially the NP in 2014 (https://www.cbd.int/abs/)
followed by the Aichi Biodiversity Targets, for the 2011-2020
period (https://www.cbd.int/sp/targets/)] were formulated. Core
are the nations’ sovereign rights over the genetic resources found
within their national jurisdiction (RuizMuller, 2018; Heinrich and
Hesketh, 2018), in addition to the necessary involvement in the
process, through agreement and Access and Benefit Sharing
(ABS), of indigenous people and local communities for granting
access based on traditional knowledge related to those resources.
The NP also specifically recognizes the traditional knowledge held
by indigenous and local communities (Secretariat of the
Convention on Biological Diversity, 2011). While such
collaborations remain contentious and are seen as a neo-
colonial form of exploration by some (Heinrich and Hesketh,
2018), here we want to highlight what opportunities exist based on
international agreements and how these can contribute to a more
equitable and mutually agreed approach at a national level.
From a different perspective, there have been numerous
position papers criticizing exploitative relationships, and this
has also been high on the political agenda of some NGOs and
other stakeholders (e.g. Dutfield and Suthersanen, 2019 and
references therein). While we recognize these problems, in this
paper we want to propose specific pragmatic solutions, beneficial
to all stakeholders, to develop relationships which result, most
importantly, in new opportunities for local communities.
In the field of natural products research, such international
efforts are important because plant species hold considerable
commercial potential; they provide a huge diversity of chemical
complexity, which is still a largely untapped source of novel
structural types for pharmaceuticals and consumer products
(Heinrich and Prieto-Garcia, 2008). However, many companies
have reduced or abandoned their interest in natural products,
because of the hurdles in accessing genetic resources (Amirkia
and Heinrich, 2015). Yet it is estimated that less than 1% of
known plants in the world have been analyzed in detail for their
pharmacological activity (Chivian and Bernstein, 2008). Such
research is based on fundamental scientific interest and offers
multiple opportunities for commercial applications. Very often
these aims are poorly understood and differentiated with basic
research being at risk due to the “restrictions” imposed by these
Abbreviations: ABS, access and benefit sharing; CBD, Convention on Biological
Diversity; CAN, Competent National Authority; CONABIO, National
Commission for the Knowledge and Use of Biodiversity; CONAP, National
Commission for Protected Areas (Consejo Nacional de Areas Protegidas
(Guatemala); DSI, digital sequence information; IRCC, Internationally
Recognized Certificate of Compliance; MAT, Mutually Agreed Terms; MTA,
Material Transfer Agreement; NFP, National Focal Point; NP, Nagoya Protocol;
PIC, Prior Informed Consent.
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international treaties (Prathapan et al., 2018). The discussion
about ABS is replete with very general statements about
challenges and the lack of opportunities to develop
partnerships that result in collaborative projects which might
yield new high value products for the international market.
Scholars have highlighted the implications of these
international treaties for international scientific collaboration.
Schindel et al. (2015) even claimed “Researchers in industrialized
countries reflect back on those open borders as a golden age of
research and development.”
Wynberg and Laird (2018) highlighted the “dramatic
differences in the pace of policy development and scientific and
technological advances” relating to ABS as well as in many other
fields. However, the implications of such differences have not been
addressed systematically (see Prathapan et al., 2018) and they
request expressis verbis that “parties to the CBD do more to raise
the legal curtain that has fallen between biodiversity scientists and
the biodiversity they strive to discover, document, and conserve.”
Furthermore, concerns were raised regarding the numerous
ambiguities and weak language (in legal terms) in the NP (e.g.
Kamau et al., 2010; Kries and Winter, 2015), problems with
regards to low priorities for the research in the treaty (e.g.
Prathapan et al., 2018) and broadly the “bureaucratic hurdles”
resulting from the NP (e.g. http://www.schlich.co.uk/latest_
nagoya_protocol.php) and other international agreements.
Overall, it is unfortunate that a major factor contributing to the
decline in the investigation of plant resources, as potential
medicines and consumer products, and for local uses in the
countries of origin, has been linked to problems with the
implementation of the very international treaties that were
intended to encourage it, namely, the CBD and the NP (see
CBD and Commercial Use). A more fundamental critique is that
the current model still maintains in essence a colonialist approach
which covers links between countries but does not provide clear
guidance on the need for arrangements at a national level
regarding equitable access to resources, for example, indigenous
knowledge (Wynberg and Laird, 2018). The treaties and the
possibilities of developing ABS mechanisms offer an
opportunity to overcome such inequalit ies through
national dialogues.
This paper is based on the fundamental premise that such
international collaborations are essential and carry opportunities
for all those involved, as long as they are based on ethical and
legal principles, as outlined in the relevant treaties. Core to any
development are economic opportunities. However, major
pharmaceutical companies avoid using the NP because of
bureaucratic access requirements and legal uncertainties
involved in negotiating international agreements (Amirkia and
Heinrich, 2015); and countries of origin have been reluctant to
work with multinational companies, because of suspicions of
“biopiracy” (Ho, 2006). Thus, the two sides, who need to make
the NP work, have both withdrawn from the opportunity. The
result is that the countries of origin are not gaining the possible
benefits from their biodiversity, and a rich source of chemical
diversity present in plant species from around the world, is
being neglected.
One reason behind this deadlock arises from a mutual lack of
understanding between provider countries and users; and also,
within governing bodies and their local populations. Companies
will have some very specific aims, but many collaborative
projects focus primarily on research, which may, but more
often does not, result in commercially useful knowledge. From
the perspective of the CBD and the NP, this does not matter.
Essential is the potential commercial application. From the
perspective of providers, commonly, the expectations that
research will result in commercially successful outcomes are
very high. However, all too often this does not reflect reality.
Consequently, this discrepancy needs to be assessed in the
planning of projects including their non-commercial and
potential commercial benefits.
AIMS AND OBJECTIVES
With a wide range of interpretations of all aspects of these
treaties and their implementation, it is essential to understand
similarities and differences in core countries which have the
potential to benefit from new ABS mechanisms. Here we look at
six provider countries in order to compare approaches and
solutions for ascertaining access under mutually understood
and accepted terms and benefits. We aim at understanding the
specific opportunities and challenges in these countries in the
context of potential commercial use of biodiversity. While it is
not a tool to define how to develop specific agreements, the paper
critically compares the approaches of Chile, Colombia,
Guatemala, México, Peru, and Panamá, defining what is
needed to achieve collaborative partnerships.
BACKGROUND
CBD and Commercial Use
The principle behind the ABS provisions of the CBD and NP is
that one country grants access to its genetic resources for
utilization by another country; and in return, shares the
resulting benefits arising from that utilization. The first issue to
understand is the nature of “benefits” and “utilization.”
Art 15.7 of the CBD refers to benefits “arising from the
commercial and other utilization of genetic resources” (emphasis
added). Thus, it is clear that commercial benefits are
contemplated. It follows, then, that if an ABS framework is to
be successful, it must attract industry from countries with a
strong research base, which is why an understanding of
commercial business perspectives is important. Also, Article 11
of the CBD requires countries to adopt measures that “act as
incentives for the conservation and sustainable use of
components of biological diversity”.
The term “utilization” is defined in the NP as research and
development. So, it is important to realize that it is not the
genetic resources or plant materials that are being
commercialized. That would represent trade of genetic
resources as commodities, which is not regulated by NP and
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CBD. For that reason, the present commentary deals with
situations in which genetic resources merely provide the
starting point for research. This is important for two reasons:
first, the relevance of intellectual property; and secondly, the
expectations of benefit.
Challenges in Cases of Commercial
Development
Establishing the level of monetary benefits that is reasonable as
part of any benefit-sharing agreement is tricky and often a major
point of disagreement between parties. This issue has been a
hurdle to successful ABS agreements in the past, often because of
misunderstandings and different interpretations of what can be
expected realistically.
The Nagoya Protocol and the Current
State of Global ABS Implementation
The NP was adopted by the Conference of the Parties to the
Convention on Biological Diversity at its 10th meeting on 29th
October 2010 in Nagoya, Japan. It entered into force on October
12th, 2014. By April 2020, the NP had 123 Parties, including the
European Union, but excluding several States and territories with
notable indigenous populations and often rich biodiversity
(Australia, Brazil, Canada, Colombia, Greenland, New Zealand,
the Russian Federation, USA, inter alia). However, CBD’s near-
universal ratification ensures that its more generic provisions for
ABS for the sustainable use of biodiversity, such as articles 1, 8
and 15, still apply to all non-Parties to the NP except the USA
and the Holy See. Besides manifold national and regional
initiatives, an ABS clearing house has also been established
within the CBD Secretariat, which assists users and providers
to implement ABS provisions (Convention on Biological
Diversity, 2019a).
Due to its recent entry into force, aspects of NP implementation
that were not solved during initial negotiation are subject to ongoing
discussion and definition among Parties. Article 31 establishes an
assessment and review mechanism to evaluate the effectiveness of
the NP. The first review adopted in Decision NP-3/1 in November
2018 established an indicator framework and reference points
against which to measure progress in future assessments
(Convention on Biological Diversity, 2018a). By July 2018, 75
Parties had legislative, administrative or policy measures on ABS
in place (including many that preceded the adoption of the NP), 44
were in the process of revising or developing new procedures to
implement the NP, and 57 had established one or more competent
national authorities. Forty-one Parties had legislative, administrative
or policy measures in place to implement fair and equitable benefit-
sharing on genetic resources held by indigenous people and local
communities (IPLCs) and 42 hadmeasures on associated traditional
knowledge. Twenty-three parties adopted measures to ensure prior
informed consent and involvement of IPLCs, representing 47% of
the Parties where IPLCs have the right to grant access to genetic
resources. Twenty one parties have taken measures to ensure that
traditional knowledge associated with genetic resources is accessed
with prior informed consent and involvement of IPLCs under
mutually agreed terms, representing 43% of Parties with IPLCs in
their country (Convention on Biological Diversity, 2018b). As of
April 2020, 1233 internationally recognized certificates of
compliance from 22 countries had been published. The vast
majority were issued by India (741) or France (233). Latin
American countries include Panama (20), Peru (16), Mexico (8),
Guyana (5), Uruguay (3), Guatemala and the Dominican Republic
(2 each), and Argentina (1) (Convention on Biological
Diversity, 2019a).
Article 10 of the NP envisions a global multilateral benefit-
sharing mechanism to address cases of genetic resources and
traditional knowledge associated with genetic resources that
occur in transboundary situations or for which it is not
possible to grant or obtain prior informed consent. Decision
NP-3/13, adopted at the third meeting of Parties, requests a study
to identify: (a) specific cases, if any, that cannot be addressed
through the bilateral approach; and (b) if identified, options for
addressing these cases, including a possible global multilateral
benefit-sharing mechanism, and make a recommendation to the
Conference of the Parties serving as the meeting of the Parties to
the Nagoya Protocol at its fourth meeting (Convention on
Biological Diversity, 2018c). While these issues seem important
from a research perspective, Parties consider these to be merely
“specific cases”, and not too relevant overall. Some countries
indicated that no cases had yet been identified of access to genetic
resources or associated traditional knowledge located in the
territory of more than one country, and that there was a need
to gain more experience on this issue (Convention on Biological
Diversity, 2018b).
One of the key challenges recognized in decision NP-3/1 is the
implementation of the provisions related to IPLCs.
Recommendations include building the capacity of Parties
related to IPLCs, and of IPLCs with respect to ABS. This may
include national mechanisms for the participation of IPLCs in
the NP, coordination and institution building within and among
IPLCs (e.g. through community protocols), and support to
IPLCs for developing minimum requirements for mutually
agreed terms and model contractual clauses (Convention on
Biological Diversity, 2018a; Convention on Biological Diversity,
2018b). For the wider legal debate especially relating to
indigenous rights (see Tobón-Franco, 2007; Endere and
Mariano, 2013; Pacheco, 2015; Pertuzé et al., 2014; Alvarado
2016; Celi, 2016).
APPROACH AND METHODS
In order to compare the situation in the six countries we used a
SWOT analysis, defining the “strengths, weaknesses,
opportunities, and threats” resulting from the current state of
the implementation of the CBD and the NP including ABS
mechanisms. A SWOT analysis is used to assess the current
position as a basis for developing a new strategy, in this case for
implementing ABS mechanism. It is followed by an internal
comparative analysis of the situation in the six countries
following the principles of a Delphi process. The strategy is
embedded in a project which focuses on the indigenous
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participation in developing ABS mechanisms in Guatemala. The
initial basis was a one-day meeting which included experts from
these countries or working with partners in these countries. The
initial analysis was then refined by each partner and developed
further. The final analysis is based on a consultative round of
discussions on various versions of the manuscript.
RESULTS AND DISCUSSION: CASE
STUDIES
Chile
The Chilean Flora and Its Uses
The flora of Chile includes over 4500 species (Rodrıǵuez et al.,
2018), is highly endemic (ca. 50%) (Cowling et al., 1996) and is
increasingly threatened (Olson and Dinerstein, 1998). The
inhabitants of Chile have a long history of native plant usage
and many indigenous groups continue to use these plants for their
subsistence, generating a large body of traditional and local plant
knowledge. Dıáz-Forestier et al. (2019) identified a total of 995
species of useful vascular plants (23% of Chile’s flora) of which
501 species are described with medicinal uses, 228 with edible
uses, 341 used for animal fodder, 300 considered ornamental, 102
used as dyes, 89 for ritual purposes, 75 for timber, and 51 species
as a source of fiber. Over 43% of the useful species are endemic to
Chile, and 4.7% are threatened (Dıáz-Forestier et al., 2019).
Implementation of the CBD and the NP
Chile is one of the countries that signed (13/06/1992) and ratified
the CBD early on (08/12/1994), but has not yet taken any steps to
ratify the NP (https://www.cbd.int/countries/profile/?country=cl).
This process is being coordinated by the Comisión Nacional del
Medio Ambiente (CONAMA) - now Ministerio de Medio
Ambiente y Servicio de Evaluación Ambiental - in its role as the
authority responsible for proposing environmental policies to the
government and as the national focal point for the CBD.
There are nine indigenous peoples in Chile that represent 9% of
its population (1.6Million). The largest one isMapuche, followed by
the Aymara, the Diaguita, the Lickanantay, and the Quechuas,
(International Work Group for Indigenous Affairs; https://www.
iwgia.org/en/chile accessed on 24/01/2020). The rural and
indigenous communities, together with socio-environmental
organizations, signed a declaration asking President V.M. Bachelet
(2006 to 2010 and 2014 to 2018) not to ratify the NP on “Access to
Genetic Resources and Fair and Equitable Participation in the
Benefits arising from its use” in order to avoid a repetition of the
internal conflicts resulting from the implementation of another
Convention (International Convention for the Protection of New
Varieties of Plants) in 2011.
Based on Chilean laws, the implementation of the NP currently
requires a consultation with Indigenous Communities and to
obtain their free and informed consent. Research projects must
give guarantees to the communities with regard to their free access
to the results of the research on native and criollas seeds, developed
in their territory by academic or other entities. Projects must also
include short term marketing mechanisms. In this way, the rural
and indigenous communities will be able to strengthen and better
contribute to the generation of sustainable local economies, and
production of healthy and safe food. (Aguilar and Alfaro, 2015).
SWOT Analysis
Within the wider framework of biodiversity, there are numerous
strengths and opportunities in Chile. However, despite the
formal ratification, Chile has not yet developed a structural
framework for the overall implementation of the CBD, a
necessary basis for the specific formulation of an ABS regime
based on previously determined objectives, goals, and priorities.
Problems in the context of ABS regulation are a particular
concern (Table 1). However, the current National Biodiversity
Strategy and the future National Biodiversity Action Plan are
steps in the right direction (Flores-Mimica and Hervé-Espejo,
2004; Püschel Hoeneisen, 2019). However, this plan does not
cover commercial aspects of such a framework.
An inter-ministerial group coordinated by the Ministry of
Environment (MMA) was set up in 2010 to study the NP, but the
process seems to have been halted since there was no
continuity thereof.
Legal Implications for Chile of the Non-Ratification of the NP
Current legal challenges include:
i. The rights of indigenous and local peoples, especially based
on uncertainties, from the ABS point of view, since there is
no regulation of access to genetic resources and traditional
knowledge,
ii. scientific research, which is hampered by a lack of legal
certainty about access; and;
iii. as a consequence, a loss of competitiveness as a country with
respect to products that could be developed from genetic
resources or traditional knowledge associated with them.
The International Union for the Protection of New Varieties of
Plants (UPOV) Convention 78 and the Seed Law 19,342 guarantee
the rights of breeders of plant varieties, but Chile lacks any specific
legislation that safeguards the rights of indigenous peoples and local
communities over their genetic heritage and traditional knowledge,
which, in the context of the NP, results inajor gaps for
implementing the treaty. Similar to other countries (e.g.
Guatemala, see below) stakeholders within Chile opposing its
ratification believe that it would become an instrument that
would only serve transnational corporations and institutions in
the global north to generate substantial benefits from the sale of new
pharmaceutical, food, beauty or other products. This is a common
fear in many biodiversity-rich countries, such as the ones included
here. Based on this assessment, they perceive that common goods
and ancestral knowledge would be privatized. This view has
solidified due to several cases of illegal access that have been
reported. A commonly quoted example is that of rapamycin, a
drug with antibiotic, immunosuppressor, and anticancer activity,
obtained from an endemic bacteria Streptomyces hygroscopicus of
Rapa Nui (formerly known as Easter Island, Chile) isolated in 1972
from soil samples taken in 1965 (Sehgal et al., 1975). The Chilean
Government does not own the genetic resource and does not receive
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benefits from its commercial exploitation. It seems that association
to the indigenous name of the island has prompted local
movements into believing its discovery came from traditional
knowledge, but this fact has never been assessed (https://issuu.
com/moevarua/docs/20_octubre2009; accessed 18/02/2020). This
development, which was completed many years prior to the
implementation of the treaties, could be seen as an example, of
how the CBD and the NP could facilitate equitable benefits, but in
Chile, it is more commonly seen as evidence for the lack of benefits
of such research for a provider country.
In Chile, there is a particular concern about Article 12.4
(parties “will not restrict as far as possible the customary use and
exchange of genetic resources by communities”) regarding the
possibility that companies could restrict people’s right to use
germplasm (seeds) or patented knowledge for common practices,
such as the exchange of seeds, collection, and cultivation of
medicinal herbs and the exercise of traditional medicine. This
concern stems out of a fear that is politically and socially rooted,
as the mentioned article clearly states the contrary. It must be
said that “as far as possible” leaves room for exploitation, which
would need to be avoided through a specific national regulation
aimed at ascertaining that traditional practices do not get
hindered due to granted access. Equally, Article 2d of the NP
opens the way to modern biotechnology, defining the use of
“biological systems, living organisms, or derivatives thereof, to
make or modify products or processes for specific use”,
contradicting the objectives of biodiversity protection set forth
in the introduction to the NP. An obvious solution would be to
clearly establish both parties’ requirements and expectations on
mutually agreed terms (MTAs) or prior informed consent (PIC).
Consequently, in Chile there are major concerns that transgenic
agricultural products, for example, from quinoa [Chenopodium
quinoa Willd), maqui (Aristotelia chilensis (Molina) Stuntz],
calafate (Berberis microphylla G.Forst.) may be the result of the
implementation of the NP.
The lack of a legal framework on access to genetic resources and
associated traditional knowledge could potentially result in major
threats relating to ABS. With the lack of an official inspection body,
this could result in a social unrest and economic insecurity,
potentially triggering civil conflicts. In general there is a climate of
distrust relating to the transmission of traditional knowledge outside
the communities, which results in an attitude of “closure” of
indigenous people for not seeing benefits from the commercial
exploitation of their traditional knowledge.
This situation discourages research collaborations between
foreign countries and Chile on Chilean genetic resources, while
at the same time still allows unauthorized use of genetic resources
and associated traditional knowledge without a fair benefit sharing
in exchange for it. Developing a suitable model of implementing
the basic principles of the NP would help to resolve these
challenges relating to property rights and resolution of conflicts
between stakeholders interested in such rights.
TABLE 1 | SWOT analysis of access and benefit sharing—Case study Chile.
Strengths Weaknesses
• Since Dec 28, 1994, Chile has been a Party to the CBD, by ratification. (R) • Chile has not signed and is not a party to the NP, nor has it an official competent
agency concerned with ABS under the terms of the NP. More broadly, Chile lacks an
official inspection body safeguarding ABS. (R)
• The Chilean flora includes over 4500 highly endemic species (ca. 50%). (B) • Chile lacks officially recognized “checkpoints” and “checkpoint communiqués”
under the terms of Article 17,1(a), (i) of the NP, as well as Internationally Recognized
Certificate of Compliance—IRCC under the terms of Article 17 of NP. (R)
• Nine hundred ninety-five species of useful vascular plants (23% of Chile's
flora), including 501 with medicinal uses, 228 with edible uses, 341 used for
animal fodder, 300 with ornamental uses, 102 used as dyes, 89 for ritual
purposes, 75 for timber, and 51 species as a source of fiber, are known. (B)
• Chile lacks a strong institutional framework for ABS. Access to genetic resource
has been nearly exclusively via contracts for academic research purposes, very few
for commercial purposes. (R)
• Chile has a well-developed Industrial Property Law, also safeguarding and
respecting the biological and genetic heritage as well as the national traditional
knowledge. (R/I)
• There is a great ignorance in the academic sector regarding knowledge of ABS
and intellectual property, generating scarce research with commercial opportunities.
(K)
• Granting of industrial property rights guarantees that this material has been
acquired in accordance with the current legal system. (R/I)
• A free and informed Indigenous Consultation on the NP (Convention C169 ILO)
has not been implemented. (R)
• Despite of a lack of an ABS framework, the Government has already entered into
individual ABS agreements, which lack definitions of benefit sharing. (I/R)
Opportunities Threats
• Chile, being a tricontinental country, presents a great cultural and biological
diversity that could be developed. (B)
• With most ecozones being fragmented and small, many endemic species are
increasingly threatened, as well as traditional knowledge associated with the Chilean
flora due to anthropogenic impact including economic activities, e.g., mining, forestry
and agriculture industries, and climatic factors, e.g., mega-droughts. (B)
• Socio-economic development and preservation of indigenous cultures, in the
extreme north and south and on Rapa Nui, with a wealth of traditional
knowledge can improve the living conditions in these regions. (B)
• The lack of a legal framework on access to genetic resources and associated
traditional knowledge could potentially result in major conflicts regarding ABS. (R)
• There is no specific ABS framework, but several proposals have been
developed (some of them drafted by the agriculture sector), and few ABS
agreements have been concluded based on general legal clauses. (I)
Common abbreviations used in all tables: A, Academic infrastructure and capacity; B, Biodiversity and its use; G, General; I, Industrial capacity and potential; K, Knowledge related to NP
and CBD, and R, Regulatory framework including the national legal/policy basis.
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Colombia
The Colombian Flora and Its Uses
Colombia is the second country in the world in biodiversity and
the first per square kilometer with more than 51,330 species.
However, the country’s unknown biodiversity may be almost
50% of its territory. It is the world’s most biodiverse country in
birds and orchids, second in plants, amphibians, butterflies, and
freshwater fish, third in palms and reptiles and fourth in
mammals (SIB Colombia, 2020).
With approximately 25,648 species of flowering plants
identified (SIB Colombia, 2020), the country has been
implementing a national plant conservation strategy that was
welcomed by the CBD in 2002. Of that total, 769 plants are
cultivated, almost 798 are under some category of threat and 400
native plants are used for food (Castellanos et al., 2017).
Colombia has 1,905,617 indigenous peoples of 87 different
ethnolinguistic groups according to its last census in 2018
(https://www.dane.gov.co/files/censo2018/informacion-tecnica/
cnpv-2018-presentacion-3ra-entrega.pdf), representing 4.4% of
its total population. The great cultural diversity found in
Colombia has resulted in a variety of uses of biodiversity. In
the case of medicinal plants, 1,656 native species have been
recorded in the literature, of which 1,442 are native to the
country, and 214 are endemic (Bernal et al., 2011).
Implementation of the CBD and the NP
In 1994 Colombia ratified the CBD through Law 165. In 1996,
Colombia, together with Bolivia, Ecuador, Peru, and Venezuela,
signed the Andean Decision 391 as a “common regime of access
to genetic resources” (Stiglitz, 2013; Sarmiento, 2014; Ortiz-
Baquero and Solano-Osorio, 2016). The Ministry of
Environment was designated as the competent national
authority in terms of access to genetic resources. Colombia
signed the NP in 2011 and has been working on its ratification
(UNDP, 2018), which is pending engagement in prior
consultat ion with indigenous and Afro-descendent
communities in the country, a process that was conceptualized
as necessary by the Council of State.
However, although not having ratified the NP, the country
has strengthened the national ABS framework through
Resolution 1348 of 2015 and Decree 1076 of 2015 that clarify
which activities require access and compile pre-existing
regulations on issues, such as biological collections and species
collection permits for non-commercial research purposes. In
2016, a manual was published with the requirements for
contracts relating to access to genetic resources and derived
products (UNDP, 2018). This manual includes information on
the procedures to be followed and the communication strategies
that research groups, universities, biotechnology companies,
institutions, and organizations need to follow in the
dissemination of information about it.
To date, 329 contracts for access to genetic resources have been
signed, of which only 11 have been for commercial purposes.
SWOT Analysis and Core Future Action Points
Compared to other countries, the regulatory aspects are less of a
problem (Table 2); instead, the industrial capacity and academic
infrastructure are core weaknesses. With a strong institutional
framework for ABS in Colombia, there should be multiple
opportunities for developing collaborative projects. However,
TABLE 2 | SWOT analysis of access and benefit sharing—Case study Colombia.
Strengths Weaknesses
• One of the top megadiverse countries globally. (B) • Access to the genetic resource has been concentrated in contracts for research
purposes, very few for commercial purposes. (A)
• Colombia has a strong institutional framework for ABS, led by the
Ministry of Environment. It has achieved important results especially in the
granting of contracts for research purposes, especially with the academy.
(R)
• Although the country has made significant efforts in regulating access to genetic
resources, with an important institutional framework, it still has great weaknesses in access
to the biological resources with access being in the hands of regional environmental
authorities, institutionally weak to process this type of permits. (R)
• The country has important policy documents, CONPES 3697 of 2011
and CONPES 3934 of 2018, which have allowed defining institutional,
legal, and economic actions and goals promoting the sustainable use of
biodiversity through access to genetic resources. (R)
• Despite of a sound academic infrastructure, there are great weaknesses in the
academic sector regarding knowledge of ABS and intellectual property, resulting in only
very few investigations with commercial opportunities. (A)
• The ‘bioeconomy' is an important axis of its development (Law 1955 of
2019 of the National Development Plan). It has prioritized actions in
research, development, and innovation, and committed important financial
resources. (R)
• The Colombian private sector is conservative and has been risk-averse in investing in
initiatives to use genetic resources. There is still distrust between academia and industry
that prevents capitalizing on important initiatives for the development of new products. (I)
Opportunities Threats
• Building further collaboration with foreign partners could be based on
the great biodiversity linked with a relatively active research program
relevant to the sustainable use of biodiversity. (A/B)
• There is still a great distrust of local communities regarding access to genetic resources
and negotiation with the private sector. This hinders development in many regions of the
country with a large presence of ethnic groups. (I)
• There is a great interest from international biotech companies, in
investing in Colombia, given the wide range of existing biodiversity, with
regions with great possibilities for doing business. (I)
• There is still a very high expectation regarding royalties resulting from access contracts
for commercial purposes, making collaborations commercially unattractive and
discouraging companies from investing in such initiatives. (I)
• The country has been diversifying its export offer; sectors with great
opportunities such as food, cosmetic, and pharmaceutical are emerging
rapidly. (I)
• Stakeholders among the local industry could be interested in the use of
biodiversity. (I)
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as in other cases, the main challenges relate to accessing
biodiversity in an equitable way based on mutual trust and
transdisciplinary and international collaboration.
The coming years will be marked by actions that seek to
concentrate efforts in regions with greater opportunities for the
“bioeconomy.” This will lead to further development of
bioproducts for different economic sectors, especially for the
agricultural, cosmetic, and food sectors. It is generally expected
that in the next years the demand for contracts for access to
genetic resources for commercial purposes will grow. The
Ministry of Environment hopes to reduce the time to grant
such contracts and also facilitate access to the biological resource
in the regions.
Guatemala
The Guatemalan Flora and Its Uses
Guatemala is one of the 19 megadiverse countries who
together host 70% of Earth’s biodiversity. The broad diversity
is mostly due to the topographic variations that occur within the
country’s borders, producing a complex variety of climatic
conditions and, subsequently, ecosystems (Byers and Lopez-
Selva, 2016). In 2001, World Wide Fund for Nature (WWF)
categorized the national area into 14 “ecoregions” (Olson et al.,
2001). This complexity contributes to making Guatemala the
Central American country with the highest number of endemic
species and a long-standing/ancient traditional knowledge
related to them. Despite of the initiatives for a Flora of
Guatemala which started mid-20th century (Paul C. Standley
and Julian A. Steyermark), the systematic recording of
biodiversity, as well as the traditional knowledge associated
with it, is far from being exhaustive and the Central highlands
are generally best known in terms of their biodiversity and its
uses/associated opportunities.
The indigenous population, comprising 21 ethno-linguistic
groups, represents around half of the country’s population
(UNHCR, 2013; CIA, 2019) and has significant ties to the
endemic flora and fauna which still holds considerable
spiritual, cultural, and economic importance. Around 79% of
the indigenous people suffer from poverty with 40% suffering
extreme poverty (CIA, 2019). Traditional ways of life are still
important, including a strong reliance on local natural resources
for daily lives. Within this context, it is clear how the
conservation of Guatemala’s biodiversity assumes a greater
social and political significance for the country.
Guatemala’s main source of income and employment is
agriculture, with a growing cattle sector expanding in the
lowlands of the subtropical rainforest (MAGA, 2016). The
expansion of monocultures, such as the African palm (Elaeis
guineensis Jacq.), and other smaller scale cultivated areas,
provides more jobs, but unsustainable use of land will
potentially irreversibly undermine the survival of the
various ecosystems.
Private interests push the boundaries of the collective goods
and land, endangering people’s livelihoods, traditional
knowledge, and environmental conservation. The political
instability and widespread corruption are the reasons behind a
generalized sense of mistrust towards authorities, even those put
in place to promote and drive conservation.
Implementation of the CBD and the NP
Guatemala signed the CBD early and on October 8, 1995, became
a party. However, the implementation of the NP has a far more
complex history. Guatemala ratified the NP in October 2014
(Decreto 6-2014, 2014). The ABS national focal point (NFP) for
Guatemala is CONAP (Consejo Nacional de Areas Protegidas),
which is also the relevant Competent National Authority (CNA).
CONAP is the authority in terms of CBD, biodiversity
regulations and initiatives, creating the Coordination
Department for Indigenous Peoples and Civil Society to
develop competence in regard to policies concerning
indigenous peoples’ rights.
Guatemala still lacks any policy in place to regulate
intellectual property rights and limitations, due in part to the
civil society hostility in this regard (Risoli, 2019). A law on
agricultural ABS regulates intellectual data but still overlooks the
issue of equitable benefits. This puts Guatemala behind all the
other Central American countries.
In 2014, Guatemala submitted the National Biodiversity
Strategy (NBS) and Action Plan for 2012-2022 (https://www.
cbd.int/doc/world/gt/gt-nbsap-v2-es.pdf), outlining the
principles for biodiversity conservation and sustainable use,
and recently submitted online the 6th National report (2019).
In the months following submission, the NBS, the national
authority CONAP started a process for the implementation of
NP in the country (even involving an UN-funded project) which
nevertheless hit a brick wall in 2016, when the NP was
temporarily suspended. The suspension came after the decree
was flagged as unconstitutional by an indigenous congressman
based on recommendation of the Gran Consejo de Autoridades
Ancestrales de los Pueblos Indıǵenas de Guatemala (GCAAG—
The Grand Council of Ancestral Authorities of the Indigenous
Peoples of Guatemala) and indigenous members of the REDSAG
(Network for Food and Nutritional Security), supported by a
number of NGOs.
The rationale for the suspension was that the NP had been
approved in a rush and without following constitutional
regulation mandating that all issues affecting indigenous
peoples should follow a consultation process (guaranteed by
the national signing of the ILO Convention 169 on Indigenous
and Tribal Peoples). Apart from the technical motivations, the
driving reason is a justifiable fear of exploitation and
discrimination of indigenous people and the wider civil society.
Based on information in the popular press, a mistaken
association between the so-called Monsanto Law (Law on
Protection of Obtaining Vegetable Materials, decree 19-2014,
regarding possible genetic manipulation and privatization of
native seeds) and the approval of the NP was made. The
“Monsanto Law” refers to the use of genetically modified
organisms and their use and is not relevant in the context of
the NP, but it does highlight the well justified fears of
exploitation. A major scandal ensued when civil society
representatives uncovered an authorization for a million
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Quetzal loan hidden within the law’s text. As a consequence, a
widespread general mistrust and opposition towards governing
bodies dealing with legislation of biodiversity (including
CONAP) followed, actively preventing the NP implementation.
The ongoing territorial dialogues with indigenous peoples that
had been taking place towards formulating a national policy on
ABS related to traditional knowledge, which were led by CONAP
and an ad hoc commission of civil representatives, stopped
abruptly. However, this group managed to publish a “Proposal
for a Policy on Genetic Resources and Biocultural Heritage”
(CONAP, 2016) and has continued lobbying to pass a specific
law related to this policy, publishing in 2018 a “Proposal for a law
for the protection of biological diversity and the biocultural
heritage of indigenous groups and local communities of
Guatemala” (CONAP, 2018a). So far, this law has not been
formally presented to the Congress. In general, there is fear that
commercialization of natural resources will lead to diminished
access for people to those same resources (either physical or due
to price increase, or increase in standardization and regulation of
something that is traditionally traded and exchanged freely). The
competent authority itself has clearly indicated that the country’s
legislation has contradicting regulations that do not guarantee
equitable ABS to indigenous groups. For this reason, it has
attempted to generate initial experiences with indigenous
groups on access to biodiversity by elaborating biocultural
inventories that can set a precedent on collective intellectual
property (CONAP, 2018b).
Other relevant norms and regulations in place in Guatemala,
in regard to biodiversity conservation and use, ABS and genetic
engineering, are: Governmental Agreement 220-2011, National
Biodiversity Policy (complemented by Decree Law 4/89),
Ministerial Agreement 117-95 (1995) on agricultural ABS
(regulating ABS for plants genetic resources, mostly for
agricultural use) and the National Biosecurity Policy (2015),
which provides guidelines in regard to genetic engineering of
national genetic resources.
Currently there is no law regulating intellectual property
matters, but they are evaluated case by case by the Intellectual
Property Registry, belonging to the Ministry of Economy, while
the Ministry of Agriculture and Livestock is the national
competent authority for the international treaty on Plant
Genetic Resources for Food and Agriculture (Muller, 2016).
SWOT Analysis and Core Future Action Points
The unclear legal situation has resulted in an ambiguous and
unfavorable environment, which hampers the development of
new opportunities. Problems in the context of regulating ABS are
a particular concern (Table 3). As in other countries, limited
communication about the principles and implementation of the
CBD’s ABS and a mistrust in the authorities in general, as well as
in institutions, has resulted in a halt of the NP and a seemingly
lack of interest in projects on the sustainable use of Guatemala’s
biodiversity. This, alongside a lack of practical tools for legal
access to genetic resources, has resulted in commercial projects/
endeavors being withdrawn and taken up in other countries with
easier or, at least, clearer stance and requirements. Looking
ahead, it seems evident that no policy affecting indigenous
peoples’ knowledge will be successfully implemented without
ample participation and representation processes, which requires
a degree of political will going beyond the NFP’s area of influence
and into the heart of state policy.
México
The Mexican Flora and Its Uses
Mexico stands out among the mega-diverse countries being the
fourth nation in terms of species richness. The country presents
almost all the climates of the planet, which, together with its
rugged topography and complex geology, allows the virtual
existence of all terrestrial ecosystems present in the world,
concentrated in only two million square kilometers. On the
other hand, two large biogeographic realms concur in the
territory: the Neoarctic , which contributes a great
representation of the species of the temperate zones of the
world, and the Neotropics, which provides many elements of
the tropical zone. As a result of the above, it is estimated that
hundreds of thousands of species inhabit the country, with a very
wide genetic variety, particularly evident in the case of cultivated
species (Sarukhán et al., 2009). The country has an estimated 544
species of land and marine mammals, it is second in terms of
mammalian species, as well as reptiles with 804 species, with
between 300,000 and 425,000 estimated insect species and 23,522
known plant species. An estimated 32% of vertebrate fauna is
endemic to the country and 52% is endemic to Mesoamerica. In
Mexico around 30 million people live in rural areas and about 12
million belong to one of 86 ethnolinguistic indigenous groups
that make up about 10% of the population (INEG, 2019).
Implementation of the CBD and the NP
Mexico has been a party of the CBD since it came into fruition
(29 December 1993) and signed the NP on February 25, 2011.
The ratification instrument was deposited on May 16, 2012,
becoming the fifth nation to ratify it and the first mega-diverse
country to do so. Although the protocol was signed nine years
ago, it has not yet been effectively implemented due to
legal lacunae.
The National Commission for the Knowledge and Use of
Biodiversity (CONABIO) served as the National Focal Point for
the Special Intergovernmental Committee of Open Composition
of the NP, yet it ceased to function at the first meeting of
the Protocol.
Now, the designated National Focal Point (NFP) is the
General Direction of the Primary Sector and Renewable
Natural Resources (DGSPRNR) of the Ministry of
Environment and Natural Resources (SEMARNAT).
The Competent National Authority (CNA) is split into six
government departments, delineated below.
The National Service of seed Inspection and Certification,
Secretary of Agriculture is responsible for the coordination of
policies, strategies, actions, and international agreements on
access, conservation, and sustainable use of plant genetic
resources (ABSCH, 2019). The General Direction for Wildlife,
Secretary of Environment and Natural Resources (SEMARNAT)
issues permits and other instruments for health, capture,
collection, research, exploitation, possession, handling,
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reproduction, restocking, import, export, release, transfer of
specimens, and derivatives of wildlife species (absch-cna-mx-
238565-1 National/Federal Oct 22, 2017). The General
Coordination of Livestock, SAGARPA issues guidelines for the
granting of genealogical registration certificates and those related
to the evaluation of the genetic value of the breeding stock used
in the genetic improvement of livestock species. (absch-cna-mx-
238023-1 National/Federal 10 Aug 2017). The General Direction
of Forest and Soil Management (DGGFyS), Secretariat of
Environment and Natural Resources (SEMARNAT) Is
responsible for granting authorizations for the sustainable use,
conservation, protection, and restoration of forest resources and
the corresponding soils, for the collection and use of forest
biological resources for scientific purposes. (absch-cna-mx-
203872-2 National/Federal 08 Aug 2017). The National
Commission for the Development of Indigenous Peoples (CDI)
guides, coordinates, promotes, supports, encourages, monitors,
and evaluates programs, projects, strategies, and public actions
for the integral and sustainable development of indigenous
peoples and communities (absch-cna-mx-203818-2 National/
Federal 08 Aug 2017). The National Commission of Natural
Protected Areas safeguards Natural Protected Areas (ANP),
genetic diversity of wild species, as well as engaging in the
preservation and sustainable use of species in some risk
category (absch-cna-mx-238008-1 National/Federal 08
Aug 2017).
Furthermore, the Government of Mexico, as an
administrative measure, created the inter-secretarial group for
the implementation of the Protocol, which is made up of 22
Federal Government Departments and has defined the current
access policy in Mexico and agreed the procedures for attention
permits/access resolutions.
By the end of 2019, the country reports eight Internationally
Recognized Certificates of Compliance (IRCC).
The NP and Basic Research Within México
Another gap in the NP is the lack of a clear definition of the
“provider” and the “user.” The protocol refers to countries, or
countries and foreign companies, but it does not define the roles
and relationship between stakeholders belonging to the same
country. This becomes especially important when dealing with
researchers (universities) who work with genetic resources and
the communities where the biological resource is located. The
question is whether such cases need to be regulated by the NP or
by other kinds of national regulation. In the case of Mexico, of
the eight IRCC, five are for research purposes in the same
country, one for commercial ones, and only two for
commercial purposes involving a foreign country. In this case,
only the last three IRCCs fit in the aim of the NP. In many cases
(medicinal plants, phytocosmetics, biological pesticides, etc.) the
initial research is done at national universities, which in the best-
case scenario results in the publication of a paper. Clearly the NP
does not cover such research, but the question is how such
research should be governed if provider and user of information
and resources are based in the same country where the genetic
resources originated. Currently, there is no consensus on this.
SWOT Analysis and Core Future Action Points
Since 1992, with the creation of the CONABIO, México has been
proactively working on the conservation and sustainable use of
biodiversity. However, issues arose translating the regulatory
framework into a national policy of ABS, and in general, there
are major concerns in México that the country and its population
will not benefit from granting access (Table 4). The NP is a
TABLE 3 | SWOT analysis of access and benefit sharing—Case study Guatemala.
Strengths Weaknesses
• The Central American country with the most endemic species and
rich in natural resources. (B)
• The suspension of the NP created a situation of uncertainty for foreign entities interested in
accessing and potentially developing local resources, pushing potential involvement abroad to
countries such as Panama with easier routes to access. (R)
• One of the countries with the biggest proportion of indigenous
population in Latin America with a long-standing tradition of use and
reliance on natural resources (conservation). (G)
• No framework in place to support the evaluation of who is the owner of TK and GRs. (R)
• CONAP's extensive experience of CBD and NP initiatives and
established position for the safeguarding of the environment and
indigenous rights. (R)
• No policy in place to regulate Intellectual Property rights and limitations. (R)
• A strong sense of community/belonging/identity around natural
resources. (K)
• Unrealistic expectations in relation to potential royalties arising from commercialization of
products deriving from genetic resources. (I)
• The NBSAP, even though published before the suspension of NP,
shows a definite intention of the State to engage with such issues. (R)
• General mistrust of authorities and a widespread misinformation on the content of the NP
manipulated for political purposes, surfing on indigenous' people malcontent. (K/R)
• There is a very weak local industry interested in the use of biodiversity. (I)
• Weak academic infrastructure. (A)
Opportunities Threats
• There is a long track record of research collaborations with a variety
of international partners based on the local expertise and international
links. (A/I)
• Major concerns about corruption and political instability result in a lack of willingness of
international stakeholders to develop links with institutions in Guatemala. (G)
• As highlighted by a previous project (Risoli, 2019), despite the
external controversial environment, it is possible to engage in ABS
implementation initiatives based in local communities. (R)
• High levels of poverty. (G)
• Agricultural expansion and unsustainable practices. (B)
• Drug cartels control over land management and development. (G)
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national law (Ley Suprema de Toda la Unión) of the entire
nation (United Mexican States). When it is incorporated into the
Mexican legal system, its application and specific invocation in
the national territory by the Mexican authorities is legally valid.
As seen in the SWOT analysis, the NP is institutionally well
developed and, legally, biodiversity is protected from activities,
such as hunting, logging, fishing, and illegal trade of species
affected by overexploitation. In the country there are restrictions
on the commercialization of at-risk species at the national level,
according to the Official Mexican Standard (NOM-059).
The legal implementation of the fair and equitable sharing of
benefits arising out of the utilization of genetic resources would
be of benefit, but México lacks a specific legal instrument that
grants attributions in the matter. Some government departments
are limited when it comes to the implementation of the protocol,
since the exact definitions that are comprised or the type of
genetic resources is not included. This is of particular concern
related to people that live in rural areas or who speak
indigenous languages.
Lacking a specific legal instrument to implement the Protocol,
it became necessary to carry out coordinated administrative
actions based on laws and procedures already in place, as well
as in compliance with the powers of CONABIO. Consequently,
permits have been issued to users who have complied with the
procedures by guaranteeing the rights of providers of genetic
resources and associated traditional knowledge in each case. As
in other countries, the regulation is ambiguous and some genetic
resources remain unregulated simply because they are not
specifically mentioned in the current laws; e.g. microorganisms
or aquatic species that are not in any category of risk, in
compliance with NOM-059-SEMARNAT-2010, or that are of
aquaculture or fishing interest. There is also a need to update the
internal regulations of each designated government department
so that, at an operational level, the CNA has staff with specific
powers to address the issues. México has not yet designated
institutions as check points to meet the provisions of
the Protocol. Similarly, a law would be required to link the
indigenous consultation component with the provisions of the
Protocol, particularly the PIC and the distinction between
collections for research purposes versus commercial use. In
general, the challenges relate, not to the legal framework as
such, but to its specific implementation, which is not
currently regulated.
México is still in the process of developing the relevant
regulatory, administrative, and political measures required for
a mutually agreeable access to genetic resources. A first core
action would be the promulgation of these administrative and
political measures in the corresponding legislation.
As of 2020, the legal instrument to regulate the utilization of
traditional knowledge associated with genetic resources, in which
measures relating to indigenous peoples and local communities
will be adopted, is being developed. The main challenge is
represented by reaching a consensus over each of the laws’
provisions; the areas of competence of the national authorities
involved and the authorization management; and the
promulgation and implementation of the legal instrument
which would be generated by the institution in charge of
this task.
In 2016, the country received financial support from the
United Nations Development Programme to increase, in a
participatory manner, the capacities of national authorities
(SRE, SEMARNAT, SAGARPA, and SE) in México, as well as
improving the legal and administrative framework in relation to
genetic resources, associated traditional knowledge and benefit
TABLE 4 | SWOT analysis of access and benefit sharing—Case study Mexico.
Strengths Weaknesses
• Mexico, as a megadiverse country, signed the NP in 2011. (B) • Mexico lacks specific legal instruments that grant attributions to the government; a
precise legal definition of what comprises a genetic resource is lacking. (R)
• There have been several ABS agreements; some of them have involved
benefit-sharing for the local communities (indigenous groups) from the
commercialization the biodiversity. (R/I)
• Further implementation of the NP is needed to legally define responsibilities of the
competent national authorities regarding ABS. (R)
• The infrastructure is well-developed, including strong academic
stakeholders and an active pharmaceutical industry. (A/I)
• Indigenous consultation, particularly Prior Informed Consent (PIC), is lacking. (R)
• There is a loophole for those cases of genetic resources that are not specifically
stated in current laws, for example, some microorganisms or aquatic species that are
not in any category of risk, in compliance with NOM-059-SEMARNAT-2010 or that are
of aquaculture or fishing interest. (R)
• In many cases, research and development processes are carried out in a different
country and not in the one the resource was obtained from; therefore, the exchange of
information between "user" country and the provider of the genetic resources, to verify
legal and legitimate access, remains a challenge. (R)
Opportunities Threats
• Once the country has fully implemented, the national regulations based on
the NP will be of great benefit especially for rural populations (around 30 M) or
to those who speak indigenous languages (around 12 M), as well as helping
the country in the preservation of biodiversity. (R)
• Major concerns about drug trafficking, corruption, and political instability result in a
lack of willingness of international stakeholders to develop links with institutions and
companies (like agricultural cooperatives) in México and specifically in regions of high
risk. (G)
• For a country in which more of the half of the population lives in poverty, a
legally binding and enforceable implementation of the NP could result in social
and environmental benefits, especially for them. (G)
• High levels of poverty result in illicit exploitation of biodiversity including clandestine
logging and illegal trade in biodiversity. (G)
• Stakeholders among the local industry could become more interested in
the sustainable use of biodiversity. (I)
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sharing, according to the institutional conditions for the
implementation of the NP. The program ended in January
2020 and resulted in some institutional coordination and a
series of training programs for federal administrative staff. In
the future the priorities for action need to be:
• Developing mechanisms for the protection of traditional
knowledge and capacity building in local and indigenous
communities;
• Raising awareness among relevant actors about the
conservation and sustainable use of biodiversity, genetic
resources, and associated traditional knowledge.
Panama
The Flora of Panamá and Its Uses
Panama is a biogeographic bridge between the flora and fauna of
Central and South America. Panama’s territory has 10,444
known species of plants that represent 3.3% of the world’s
diversity. Of these, 9,520 are vascular and 938 species are ferns
and related groups; of the 924 non-vascular plants, 796 are
species related to mosses. The endemic species of Panama
amount to 1,300, of which 1,176 are plants. Panama has 21
times more plant species per km2 than Brazil (National
Biodiversity Strategy of Panama, Ministry of Environment,
2018), ranking 11th in biodiversity per land area. These make
Panama an attractive party for those seeking opportunities for
discovery of active molecules.
Different species of flora in Panama are used for food,
cultural, and medicinal use among different indigenous and
other minority groups which according to the 2010 National
Census represent 12.3% of Panama’s population (INEC/UNFPA,
2010). These include Afro-descendants and eight indigenous
groups: Kuna, Ngäbe, Buglé, Teribe/Naso, Bokota, Emberá,
Wounaan, and Bri Bri. There have been a number of efforts to
document some of these uses, although few have focused on their
commercial potential (Chıźmar et al., 2009; Caballero-George
and Gupta, 2011; Bermúdez and Ramos Chue, 2014; ANCON,
2017; Ross et al., 2019).
Implementation of the CBD and the NP
Panama’s National Assembly ratified the NP on October 12,
2012. Prior to its ratification, in 2005, a decree regulating Article
71 of Panama’s General Environmental Law (Law 41 of 1998) on
the use and control of genetic resources was issued. However,
this law did not help to promote collaboration and stakeholders
requested its revision. In 2009, Executive Decree no 25 of April
29 enhanced the regulations on use, access, and control of genetic
resources. The latter was reviewed and a new ABS Executive
Decree was issued in 2018. Panama’s focal point for the NP is the
Ministry of Environment which established SARGEB (Section
for Access to Genetic and Biological Resources) to be in charge of
norms, regulations, and controls. This section of the Ministry of
Environment issues permits to applicants to conduct research
with commercial and non-commercial objectives and is the
contact with the CBD clearing house.
Molecules found in species under research in Panama have
already been the subject of international ABS agreements. New
active compounds have been identified, a repository of
microorganisms has just been launched and several contracts
with international companies have been signed (Biobanco, 2019).
SWOT Analysis and Core Future Action Points
Undoubtedly, Panama has taken important steps to put in
practice the ABS contemplated in the NP (Table 5). Its large
biodiversity, more than a decade of research on natural products
with agreements in place with local communities, and a
straightforward support of its government, place Panama in
the forefront of the implementation of the ABS. From the
perspective of a commercial use, the level of royalties is a
realistic expectation and it is one of Panama’s key strengths
from this perspective. More refinement needs to be done to fill
gaps that would prevent delays in the interpretation of some
sections of the recently-issued decree. What matters the most is
that all the stakeholders are acting in good faith and willing to
comply with the ABS to make Panama a model for the rest of
the world.
Developing a Collaboration between Panama and an
External Partner—A Case Study
The ABS process in Panama, and challenges encountered, can be
illustrated with one practical example of a project. With the
financial support of the German Agency for International
Cooperation (GIZ) under a regional ABS project, ANCON (the
National Association for the Conservation of Nature), an
environmental NGO in Panama prepared a Catalogue of
Native Species with commercial potential found in their largest
private reserve (Panama’s largest privately owned reserve), which
prompted the interest of a company in the UK. Thanks to the
coordination efforts of GIZ, a Memorandum of Understanding
was signed in 2018 between ANCON, a research institute
(INDICASAT AIP), and Indigena Biodiversity Ltd., a UK
facilitator specializing in ABS, to conduct research on the
species highlighted in the catalogue. The parties quickly
identified their roles and after a short negotiation process, they
executed a MAT for a R&D project that included an additional
research party based in the UK, as explained below.
An access application was filed involving a plant species
which is a natural antimalarial, but with a poor therapeutic/
toxicity ratio. The species’ samples could be collected through an
application filed by ANCON; INDICASAT was then in charge of
extracting and testing the material to be exported through
Indigena Biodiversity. The UK-based third-party research
partner was to investigate novel compounds, derivatives of the
natural ones extracted from the plant samples, with improved
antimalarial activity.
It is important to highlight that, in order to get to this point, it
was critical to first establish an effective local partnership to seek
common ground between the commercial entity in the United
Kingdom and the two stakeholders in Panama. The parties
initially differed on some issues, but through effective and
thoughtful communication, collaborations were established.
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Contacts were also made with the CBD Focal Point in Panama,
represented by the relevant government Ministry of
Environment, MiAMBIENTE, Department of Biodiversity and
Wildlife. The partnership that was developed implemented a
series of core principles and mutually agreed terms. Some key
observations were:
• Local research
Access regulations require that some research be carried out
in Panama. Local involvement is considered by Panama
partners as part of the non-monetary benefits, including the
opportunity for scientific publications. The project was able to
comply with that requirement by having extraction and testing
carried out locally. That modest contribution was acceptable to
one UK research partner. However, a second UK company was
not willing to delegate those steps, resulting in a lost
opportunity for both parties.
• Access application
The formal requirements of an access application in Panama
are reasonably modest, although names of individual UK
researchers are requested, as well as identification documents,
including notarized copies of passports. This process, without a
knowledgeable local partner, may deter a less committed user.
The application took about 6 months to be granted.
A permit for commercial research requires a MAT
agreement to be in place. However, it is possible to initiate
the process by obtaining a permit for non-commercial research
in order to collect material; and then re-apply when terms have
been negotiated, and there is some evidence of commercial
potential. Although it might seem duplicative, and somewhat
illogical, it is a pragmatic work-around for the common
problem of MAT timing.
• Level of benefit-sharing
At the time of the access application for this project, there
was a benefit-sharing requirement of a minimum 1% royalty of
net sales among the parties involved. With the revised ABS
decree of 2018, a 1% royalty of net sales for the government was
established, to avoid a long negotiation process. An overall
percentage royalty has been negotiated, but the distribution of
that figure between the stakeholders has not been finalized.
• Traditional Knowledge
The species that is the basis for this project is widely used
throughout Panama, so that any traditional knowledge is
nationally disseminated and not attributable to any
indigenous community. Whether such disseminated
traditional knowledge gives rise to a benefit-sharing
obligation under CBD/NP is an open question. However, the
parties in this project wish to follow the broad principles of the
CBD, so plan to put a proportion of any benefit into a
community fund.
• Intellectual Property
There was a broad consensus about IP issues. On a practical
level, however, the issue was more related to pressure to share
IP ownership derived from the extraction and testing activities.
TABLE 5 | SWOT analysis of access and benefit sharing—Panama.
Strengths Weaknesses
• Before ratifying the NP, Panama had already implemented ABS projects
through interinstitutional and multi-stakeholder agreements. This led to
Panama being the first country ever to receive funding under the CBD
convention. (R)
• Working with traditional knowledge of indigenous groups is still a challenge. The lack
of trust by indigenous people might hinder negotiations, to the point where external
stakeholders could only look for opportunities outside indigenous territories. (G)
• Panama ratified the NP in 2012. An executive decree regulating access
to genetic resources was issued in 2009 and reviewed in 2018, indicating a
very high level of experience in translating the international agreements into
national practice. (R)
• The sharing of benefits is not well understood by the general population. (K)
• Panama has a network of research institutions already collaborating with
local environmental NGOs and the government in order to ensure that CBD
guidelines are compatible with stakeholder requirements. (A)
• The traditional knowledge or rights of some minorities might be in conflict with the
potential contribution to humanity of that knowledge. (G)
• The new ABS decree has established a level royalty for the Government
of 1% of net sales, which is acceptable to the relevant industries. (R)
• The inventory of traditional knowledge is incomplete. Traditional knowledge is
anecdotal and needs to be registered. (A)
• The fact that the decree does not indicate the geographic or jurisdictional extension of
the benefit rights of the traditional knowledge means that demands could arise from
members of the same ethnic groups located outside of the collections site(s) of the
traditional knowledge owners. (R)
Opportunities Threats
• There is considerable commercial interest in working in Panama. (I) • When governments have to negotiate MATs on behalf of both communities and
industries, the former could perceive that the government is not protecting their right,
resulting in internal conflicts within the country. (R/G)
• Local research organizations have experience in bioprospection
studies. (A)
• The well-established democracy of Panama and its stable economy give
confidence to the industries interested in working with Panama with shared
resources under ABS rules. (R)
• There are reputable and ABS knowledgeable organizations other than
the Government, the traditional knowledge owners, and the Industry that
help to ease the lack of trust of the negotiation processes, especially
prevalent within the indigenous groups. (R)
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However, this is all part of the negotiation process. It is well
established that mere testing does not constitute an inventive
contribution and that was eventually accepted.
• Mutually Agreed Terms
Once the good working relationship was established, although
there were issues to resolve, from a commercial perspective,
obtaining a MAT agreement was no more difficult than any
other negotiation. The partners were free to consider and debate
all the issues. Terms were successfully agreed within 6 months.
• Prior Informed Consent
A good partnership of trust also facilitated the granting of a
PIC. Given that the landowner promotes the sustainable use
of Panama’s natural capital through biocommerce and
bioprospection projects, as activities that could bring
significant benefits to communities and to biodiversity
conservation, it was straightforward to draft and agree a simple
PIC document. One month from start to finish. As stated above,
this project did not involve associations with any specific
indigenous community, but the local partnerships that are in
place provide the basis for future community collaborations.
ABS regulations in Panama still need some enhancements to
attract foreign industry, but the present system is workable for
motivated users, as exemplified in this case study.
Peru
The Peruvian Flora and Its Uses
Peru harbors an estimated 78 of the 107 eco-regions of the world,
having 17,143 taxa of spermatophytes in 2,485 genera and 224
families; the flora of the country represents 10% of the world’s
total, of which 30% is endemic (Bussmann and Sharon, 2014).
Peru is the fifth country in the world in number of plant species
with known properties utilized by the population (4,400 species)
with 1,400 species described as medicinal (Brack Egg, 2004).
Peru’s indigenous groups make up from 26-30% of its total
population depending on the quoted source (Brack Egg, 2004),
with 95.8% of these located in the Andean region and 3.3% in the
Amazon. In the latter region alone, there are more than 65 ethnic
groups classified into 16 language families. Modernization results
in an enormous loss of traditional knowledge relevant to the
indigenous peoples and of great value to the science and
technology of Peru (Bussmann, 2013). In all Peruvian
indigenous groups, plant knowledge is of extreme practical
value; and also reinforces national identity and values, which are
being lost in the complementary processes of modernization and
globalization. Medicinal plant commerce in Peru is a major
economic resource with 510 medicinal plants and 974 remedies
of mixtures recorded (Bussmann and Sharon, 2007; Bussmann
and Sharon, 2014). Peruvian national sales of natural products
derived from medicinal and aromatic plants are steadily growing
and now exceed $400 million per year (UNCTAD, 2018). This
offers huge opportunities for the country that could largely benefit
from an efficient and effective implementation of an ABS scheme.
Implementation of the CBD and the NP
Peru ratified the CBD on 29 December 1993 and has been party
to the NP since its creation in 2014. The legal framework for its
application in the country is built upon the following laws: a)
Law no. 27811 on the Regime for the protection of collective
knowledge of indigenous peoples related to biological resources;
b) S.D. N° 003-2009-MINAM Supreme Decree that approves the
Regulation R.M. no. 087-2008-MINAM for Access to Genetic
Resources; c) Decision no. 391 of Andean Community
establishing the Common Regime on Access to Genetic
Resources; d) Decision N° 486 of Andean Community
Establishing the Common Industrial Property Regime; and e)
Law N° 28216 on the protection of access to Peruvian biological
diversity and the collective knowledge of indigenous peoples.
Peru’s ABS National Focal Point (NFP) is the Ministry of
Environment (MINAM) that operates through five Competent
National Authorities (CNA). One of them is MINAM itself,
while the others are the National Forest and Wildlife Service
(SERFOR), the National Institute of Agricultural Innovation
(INIA), the Ministry of Production (PRODUCE), and the
National Institute for the Defence of Free Competition and the
Protection of Intellectual Property (INDECOPI).
Peru’s checkpoints are The Directorate of Inventions and New
Technologies (DIN) of INDECOPI, and “TheNational Commission
Against Biopiracy” (CNBio) that exercises control over illegal access
to genetic resources and associated traditional knowledge.
So far, Peru has not issued any ABS contract for commercial
purposes—though it has issued sixteen Internationally
Recognized Certificates of Compliance (IRCCs) for non-
commercial research. To date there are also three applications
submitted to INIA currently under revision that are expected to
lead to new IRCCs in the next few months (MINAM, 2019).
SWOT Analysis and Core Future Action
Points
As a signatory to the NP with a few signed contracts and being
well recognized internationally for its achievements in fighting
biopiracy, Peru has a strong basis for collaboration, even though
the enforcement of Peruvian rights, for example relating to the
use of dragon’s blood (Croton lechleri Müll.Arg.), maca
(Lepidium meyenii Walp.), and sacha inchi (Plukenetia
volubilis L.), remains unresolved. As in other countries, core
concerns relate to the lack of information about the potential and
limitations of ABS-projects. Peru is struggling to update its
procedures and regulations in order to provide a timely
response to researchers and other interested parties that
request formal access to genetic resources (Silvestri, 2016; Friso
et al., 2020) and the financial expectations are seen as being
unrealistic. So regulatory uncertainty is a core concern (Table 6).
Starting in April 2018, an internationally funded training and
implementation project is being carried out to put into practice
the NP in Peru, addressing many of the previously reported
weaknesses and threats. Additionally, a national communication
strategy is being implemented to disseminate among indigenous
peoples the norms and mechanisms on protection of traditional
knowledge and provide them with the necessary know-how to
become involved in access negotiation.
In addition, MINAM is proposing a new regulation for the
access to genetic resources (MINAM, 2019). Among the main
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changes of this new law, whose overall objective is to facilitate
research and mark a clear difference between access for non-
commercial and commercial purposes, there is an additional
exemption for basic non-commercial research related to the
identification, delimitation and classification of species for
taxonomic, systematic, and phytogeographic purposes. The new
law also aims at giving greater importance to the National Support
Institutions, specifying their role, rights and obligations when
assisting foreign applicants in access activities (Friso et al.,
2020). Changing the law, however, is only one step toward the
correct implementation of NP in Peru; even more important
would be the training of the public officials involved in this area,
to facilitate and speed up the overall ABS process for researchers or
private companies interested in passing through this mandatory
procedure. A training program delivered by international experts
coming from those countries where the NP has been better
implemented could be therefore recommendable.
OVERALL CONCLUSIONS
Both the CBD and the NP are crucial elements for developing
equitable partnerships among countries with a focus on the
potential benefits of products resulting from basic and applied
research on such resources. The nearly universal adoption of the
CBD and the widespread acceptance of the NP have changed the
frameworks of collaboration and provide a much better basis for
collaborations aiming at sustainable and equitable development of
resources. Using biodiversity in the development of high value
products remains a very promising and, at the same time,
contentious area. It is a fast developing area of discussion also
linked to technological changes. Thus, we need to be aware that
genetic resources can now be accessed as digital sequence
information (DSI) rather than as biological material
(Convention on Biological Diversity, 2019b). Here we reiterate,
that any ABS framework will need to take into account the
consensus view that: “Benefit-sharing arrangements for
commercial and non-commercial use of DSI should reflect the
same or similar benefit sharing obligations as those attached to
biological materials” (Convention on Biological Diversity, 2019b).
Here we draw upon current observations from six provider
countries in Latin America to identify some of the hurdles; and
provide recommendations for a way forward.
In this comparative analysis, some obvious outcomes are
relevant. In general, all countries have a high or very high
biological diversity and most also have a considerable cultural
diversity, as seen in the existence of indigenous groups mostly
occupying biodiverse-rich territories. The hurdles to creating
opportunities from that biological and cultural diversity fall into
the following categories.
1. NP implementation
The first challenge, common to all the case studies, is that
the political framework and the implementation of NP policies
TABLE 6 | SWOT analysis of access and benefit sharing—Case study Perú.
Strengths Weaknesses
• The Peruvian Amazon holds great biodiversity, and over 1000 medicinal
and food plants with commercial potential have been recorded. (B)
• There is generally poor information about the legal framework for access to genetic
resources and associated traditional knowledge, and indigenous and local communities
have no control over an illegal access by national or foreign users. (K)
• As a signatory to the NP with a few signed contracts, Peru is ahead of
other signatory countries. So far, the application of the NP has generated
both monetary benefits and non-monetary benefits, the latter considered
greater than the former. (R)
• The ambiguity of Peruvian regulations generates concerns for many stakeholders. (R)
• Peru's CNBio is recognized internationally for its achievements in fighting
illegal extraction of biodiversity. (R)
• Peru is struggling to update its procedures and regulations in order to provide a timely
response to researchers and other interested parties that request formal access to
genetic resources. (R)
• The National Council of Science, Technology and Technological
Innovation (CONCYTEC), the General Directorate of Environmental Health
(DIGESA), and the Directorate General of Medicines, Supplies and Drugs
(DIGEMID) are all competent authorities potentially able to verify and monitor
the stages of research, development, and commercialization following an
ABS agreement. NGOs and international cooperation agencies are well
established to complement this effort, helping to balance the power relations
between North and South in the field of intellectual property and distribution
of benefits. (R)
• The mandatory monetary benefits (5% to provider organization and 10% of gross
sales to the national Fund for the Development of Indigenous Peoples) are considered too
high from a commercial perspective. (R)
• There is a relatively weak local industry interested in the use of biodiversity. (I)
Opportunities Threats
• Peru could participate much more actively in the research and
development processes relating to patenting of plants and biological
materials in collaboration with foreign partners from more developed
countries. (A/I)
• Gaps between the regular access that passes through the ABS system and ones
outside of it pose major risks for R&D. (R)
• Existing examples of products under development offer the chance to
demonstrate how collaborative projects can be developed. (I)
• Peru's neighbors such as Colombia and Brazil have not signed up to the NP and
international companies, and researchers can access there the very same genetic
resources with the associated traditional knowledge avoiding the complexity of the
Peruvian procedure. (R/G)
• Inflexible attitude of regulators can crush well-intended development initiatives (like
Biotrade). (R)
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can in itself produce contentious problems. Often, there seem
to be limited or no benefits from implementing the NP.
Clearly, there are far fewer parties that have ratified the NP
as compared to the CBD. The NP demands the creation of a
complex regulatory framework to oversee its implementation,
which can cause both internal social conflict and deter
international investment, subsequently defeating the
objective of the CBD. Since many provider countries have a
rich biodiversity, a user from another country can choose
between different countries. Consequently, from the
perspective of competing macroeconomic interests,
implementation of the NP can in fact be detrimental, since
countries which offer “easier” opportunities for access may
benefit commercially. Yet, at the same time, the treaties offer an
opportunity to implement new, more equitable policies at
national level. It calls for processes which empower
participants and provide platforms for developing a mutually
agreed national strategy. Many countries, including Panama
and Guatemala, are making efforts to take on board some of
these policies. Although beyond the scope of the present
comparative analysis, the regulatory framework in question
needs to be integrated into a broader set of government
policies and activities, including the need for protection,
redistribution, and access to land for indigenous people and
an equitable sharing of potential economic benefits.
2. Expectations of benefits
The second hurdle observed in many of the countries in
our analysis is an unrealistic expectation of the level of
benefit. It is the interests of biodiversity-rich countries to
stimulate ease of use of the CBD to generate benefits from
their genetic resources which is equitable to all stakeholders.
The benefits may be monetary, as well as technological
development, and often access to new medicines relevant to
local populations. However, if expectations are seen as
unrealistic, potential users will be deterred. To encourage a
successful application of the CBD and NP, users and
providers of genetic resources need to understand each
other’s perspective. The inclusion of non-monetary benefits
in bilateral agreements could help to establish trust between
the provider community and the user party. Benefits, such as
exchange of knowledge and one-off or continued support for
local projects/initiatives, could be provided independent of
commercial outcomes. This could encourage long lasting
collaborations as a benefit delivered at a local level.
3. Indigenous communities and traditional knowledge
Since biodiversity and the land are tightly connected with
people’s livelihoods, engagement with their environment could
provide an impetus for local development, provided that a new
basis for collaboration between stakeholders is developed and
that this is communicated in a transparent way. There is a risk
that the NP creates more endogenous civil unrest than it
provides consensus among indigenous peoples and within
countries. The problem can be more exaggerated in countries
where there is less political representation of indigenous
peoples. The experience of hundreds of years of exploitative
relationships cannot be overcome through international treaties
and indigenous groups and other national stakeholders often
see such international treaties as a neo-colonial mechanism.
Recommendations
Drawing together the issues we have identified and based on the
fundamental ethical and legal principles as outlined in the
treaties, key requirements for a successful framework to
implement CBD and NP include:
• A country’s ABS regulations should provide a framework that
is attractive to foreign basic and applied research as well as
commercial entities including legal clarity;
• Realistic expectations of the level of benefit available from
commercialization;
• The need to incentivize partnerships with industry in user
countries and to simplify procedures and allow freedom to
negotiate;
• A more systematic approach ascertaining that non-
commercial benefits to communities and regions are
implemented providing direct local benefits;
• The management of ABS-related perceptions and the
establishment of functional partnerships between
stakeholders, in particular indigenous people and
communities in provider countries;
• Participatory approaches including the recognition of
fundamental rights of the often-marginalized people who
have been the custodians of the local biodiversity and the
associated knowledge for centuries;
• Particular exemptions will be needed for the assessment of the
safety of herbal medicines, especially in the context of local
uses of toxic species (Michl et al., 2014);
• Professional development of stakeholders in the principles of
the CBD and NP and the respective implementation at a
national level.
The effective formulation of a legal regime of access to genetic
resources requires the participation of a large number of interest
groups and experts. The discussion on how to regulate genetic
resources should be carried out through a national planning
process, as required by Article 6 of the CBD, and it should be
based on a mechanism which results from a broad consensus on
the strategic national goals and how to achieve them.
Government entities from different sectors must participate in
the process, as well as representatives of the scientific community
and the private sector (for example, pharmaceutical and
agricultural companies), indigenous people/communities and
NGOs. A core concern relates to the challenges associated with
the consultation processes with indigenous groups, an
unresolved problem in several of the countries presented here,
including Chile, Guatemala, México, and Colombia.
Such a process also allows the establishment of broader
objectives and national policies, while facilitating the
evaluation of existing institutions, laws, and policies. Since the
regulation of access to genetic resources is a new area of
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legislation, few countries have the necessary institutions and
resources for its implementation. Developing this capacity
requires a long-term process and, therefore, it is vital to start it
as soon as possible. However, considering the elements
mentioned above, it is clear that there are tensions between the
urgent need to take action and the complexity of the process.
With the analysis of the implementation of ABS mechanisms in
these six countries, we were able to show that—in order to secure
benefits from the NP, most importantly—a national strategy is
needed that facilities a better understanding of the treaties and
the resulting opportunities for a more equitable development.
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protección de los recursos genéticos: desafios y perspectivas en Uruguay a
partir de la implementación del protocolo de Nagoya. Rev. Direito
Internacional 13 (2), 117–131.
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Genéticos y participación justa y equitativa en los beneficios que se deriven de
su utilización: cuatro retos para su implementación en paıśes de América
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